Danielle Brill
Stock Analyst at Truist Securities
(3.86)
# 609
Out of 5,179 analysts
104
Total ratings
44.09%
Success rate
11.66%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Hold | $83 | $77.82 | +6.66% | 1 | Mar 18, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $17 | $7.02 | +142.17% | 1 | Mar 18, 2026 | |
| MAZE Maze Therapeutics | Initiates: Buy | $68 | $30.38 | +123.83% | 1 | Mar 18, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $63 → $110 | $81.13 | +35.58% | 3 | Mar 9, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $114 → $83 | $60.09 | +38.13% | 8 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $86 → $95 | $69.70 | +36.30% | 4 | Feb 25, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $169 → $140 | $128.32 | +9.10% | 9 | Feb 17, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $38 | $28.70 | +32.40% | 3 | Jan 29, 2026 | |
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $29.35 | +104.43% | 3 | Jan 8, 2026 | |
| IMVT Immunovant | Maintains: Hold | $16 → $22 | $23.98 | -8.26% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $45 | $26.54 | +69.56% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $535 → $530 | $317.36 | +67.00% | 3 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $190 | $112.37 | +69.08% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $8.67 | +442.10% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $433.07 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $18.56 | +29.31% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $14.77 | +252.07% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $18.16 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $54.14 | +45.92% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $7.76 | +131.96% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $19.97 | +651.13% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $183.84 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $691.40 | -12.50% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $20.75 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $54.48 | -8.22% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $29.43 | +73.29% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $6.38 | +1,467.40% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $66.13 | - | 9 | Sep 18, 2023 |
Apogee Therapeutics
Mar 18, 2026
Initiates: Hold
Price Target: $83
Current: $77.82
Upside: +6.66%
Climb Bio
Mar 18, 2026
Initiates: Buy
Price Target: $17
Current: $7.02
Upside: +142.17%
Maze Therapeutics
Mar 18, 2026
Initiates: Buy
Price Target: $68
Current: $30.38
Upside: +123.83%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $63 → $110
Current: $81.13
Upside: +35.58%
Disc Medicine
Feb 27, 2026
Maintains: Buy
Price Target: $114 → $83
Current: $60.09
Upside: +38.13%
BridgeBio Pharma
Feb 25, 2026
Maintains: Buy
Price Target: $86 → $95
Current: $69.70
Upside: +36.30%
Neurocrine Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $169 → $140
Current: $128.32
Upside: +9.10%
Centessa Pharmaceuticals
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $28.70
Upside: +32.40%
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $29.35
Upside: +104.43%
Immunovant
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $23.98
Upside: -8.26%
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $26.54
Upside: +69.56%
Jan 8, 2026
Maintains: Buy
Price Target: $535 → $530
Current: $317.36
Upside: +67.00%
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $112.37
Upside: +69.08%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $8.67
Upside: +442.10%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $433.07
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $18.56
Upside: +29.31%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $14.77
Upside: +252.07%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $18.16
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $54.14
Upside: +45.92%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $7.76
Upside: +131.96%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $19.97
Upside: +651.13%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $183.84
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $691.40
Upside: -12.50%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $20.75
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $54.48
Upside: -8.22%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $29.43
Upside: +73.29%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $6.38
Upside: +1,467.40%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $66.13
Upside: -